How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 324-328

  Husain, Aliya N ^a   Mirza, M Kamran ^a   Gibbs, Allen ^b   Hiroshima, Kenzo ^c   Chi, Yiqing ^a   Boumendjel, Redouane ^a   Stang, Nolwenn ^d   Krausz, Thomas ^a   Galateau Salle, Francoise ^d  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Laboratoire d'Anatomie Pathalogique   (France)

Author keywords

Epithelioid mesothelioma; Fibrosing pleuritis; GLUT 1; Malignant mesothelioma; Mesothelial hyperplasia; Sarcomatoid mesothelioma

Indexed keywords

EPITHELIOID MESOTHELIOMA; FIBROSING PLEURITIS; GLUT-1; MALIGNANT MESOTHELIOMA; MESOTHELIAL HYPERPLASIA; SARCOMATOID MESOTHELIOMA;

CELL PROLIFERATION; COOPERATIVE BEHAVIOR; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; EPITHELIUM; FIBROSIS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; MESOTHELIOMA; PLEURA; PLEURISY; RETROSPECTIVE STUDIES; SARCOMA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84894230692     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.009     Document Type: Article

References (25)

1. Shen J., Pinkus G.S., Deshpande V., Cibas E.S. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009, 131(4):516-523.
2. Ikeda K., Tate G., Suzuki T., Kitamura T., Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol 2011, 39(6):395-401.
3. Hasteh F., Lin G.Y., Weidner N., Michael C.W. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010, 118(2):90-96.
4. Soini Y., Järvinen K., Kaarteenaho-Wiik R., Kinnula V. The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 2001, 12(9):1239-1245.
5. Rascoe P.A., Jupiter D., Cao X., Littlejohn J.E., Smythe W.R. Molecular pathogenesis of malignant mesothelioma. Expert Rev Mol Med 2012, 14:e12.
6. Taheri Z.M., Mehrafza M., Mohammadi F., Khoddami M., Bahadori M., Masjedi M.R. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2008, 132(4):694-697.
7. Ramael M., Buysse C., Van den Bossche J., Segers K., Van Marck E. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992, 167(1):1-4.
8. Ikeda K., Tate G., Suzuki T., Kitamura T., Mitsuya T. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010, 41(5):745-750.
9. Shi M., Fraire A.E., Chu P., et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011, 35(6):878-882.
10. Kato Y., Tsuta K., Seki K., et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007, 20(2):215-220.
11. Gagliardi S., Davin A., Ricca I., et al. A new GLUT-1 mutation in a family with glucose transporter 1 deficiency syndrome. Mov Disord 2012, 27(6):804-805.
12. Wann J.G., Lin C.-S., Chang L.-C., et al. Enhanced expression of glucose transporter 1 on erythrocyte membrane in hemodialysis patients: the possible role in erythrocyte ascorbate recycling. Am J Kidney Dis 2006, 47(6):1055-1063.
13. García-Alvarez I., Garrido L., Fernández-Mayoralas A. Studies on the uptake of glucose derivatives by red blood cells. ChemMedChem 2007, 2(4):496-504.
14. Salla J.T., Johann A.C.B.R., Lana A.M.A., do Carmo M.A.V., Nunes F.D., Mesquita R.A. Immunohistochemical study of GLUT-1 in oral peripheral nerve sheath tumors. Oral Dis 2008, 14(6):510-513.
15. Linden K.C., DeHaan C.L., Zhang Y., et al. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2006, 290(1):F205-F213.
16. Devraj K., Klinger M.E., Myers R.L., Mokashi A., Hawkins R.A., Simpson I.A. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res 2011, 89(12):1913-1925.
17. Baumann M.U., Deborde S., Illsley N.P. Placental glucose transfer and fetal growth. Endocrine 2002, 19(1):13-22.
18. Patiño-Seijas B., Lorenzo-Franco F., Rey-Sanjurjo J.L., González-Cuesta M., López-Cedrún Cembranos J.L. Vascular lesions: GLUT-1 expression as a diagnostic tool to discriminate tumors from malformations. J Oral Maxillofac Surg 2012, 70(10):2333-2342.
19. Sasaki H., Shitara M., Yokota K., et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep 2012, 5(3):599-602.
20. Kobayashi M., Kaida H., Kawahara A., et al. The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients. Clin Nucl Med 2012, 37(5):447-452.
21. Lagana S.M., Taub R.N., Borczuk A.C. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012, 136(7):804-809.
22. Airley R., Evans A., Mobasheri A., Hewitt S.M. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 2010, 192(3):133-138.
23. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53(4):233-256.
24. Lee A.F., Gown A.M., Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol 2013, 37(March (3)):421-426.
25. Monaco S.E., Shuai Y., Bansal M., Krasinskas A.M., Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011, 135(4):619-627.